Dick Davis Digest 12/29/97
***Special thanks to Karl Drobnik
Volume 16, Issue 374 December 29, 1997
Quick Picks #4
Chromatics: The Science Of Color
"Chromatics Color Sciences (CCSI 15 3/4 OTC) is developing Colormate, a technology that applies scientific color measurement to skin," says Karl Drobnic (Venture Returns, 1855 NW Tyler Ave., Corvallis, OR 97330, 24 issues, $75, 12/2/97).
"A target market for Colormate is the detection and monitoring of certain diseases, including bilirubin infant jaundice. Chromatics' global market for this one disease is estimated at $1 billion _ if it makes the right distribution deal with a major medical device sales company. FDA clearance for bilirubin infant jaundice use has been obtained.
Bilirubin is a liver disease that occurs shortly after birth. It affects almost all premature babies, and about half the rest. Every U.S. baby is tested for it. Non-invasive tests that don't involve blood draws have major safety advantages. The bilirubin test is the first of several 'killer apps' that could make Chromatic's patents dominant in color science.
Other major diseases for which Chromatics may develop detection technology are anemia, hepatitus and TB.
In addition to medical uses, the firm's technology can be used in such areas as quality control in manufacturing, cosmetics, dentistry, and even color coordination in consumer products. Chromatics shares should be in the $25-30 range by mid-1998, and much higher in 1999. Chromatics is a high risk/high reward speculative buy." |
